SARTORIUS STEDIM BIOTECH (56S1.DE) Fundamental Analysis & Valuation
FRA:56S1 • FR0013154002
Current stock price
151.5 EUR
-8.2 (-5.13%)
Last:
This 56S1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. 56S1.DE Profitability Analysis
1.1 Basic Checks
- 56S1 had positive earnings in the past year.
- 56S1 had a positive operating cash flow in the past year.
- Each year in the past 5 years 56S1 has been profitable.
- In the past 5 years 56S1 always reported a positive cash flow from operatings.
1.2 Ratios
- 56S1 has a Return On Assets (3.28%) which is in line with its industry peers.
- 56S1 has a Return On Equity (6.53%) which is comparable to the rest of the industry.
- The Return On Invested Capital of 56S1 (6.19%) is better than 62.50% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for 56S1 is in line with the industry average of 7.18%.
- The 3 year average ROIC (5.23%) for 56S1 is below the current ROIC(6.19%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.28% | ||
| ROE | 6.53% | ||
| ROIC | 6.19% |
ROA(3y)3.15%
ROA(5y)7.45%
ROE(3y)7.54%
ROE(5y)16.68%
ROIC(3y)5.23%
ROIC(5y)11.87%
1.3 Margins
- The Profit Margin of 56S1 (8.99%) is better than 68.75% of its industry peers.
- 56S1's Profit Margin has declined in the last couple of years.
- With a decent Operating Margin value of 17.88%, 56S1 is doing good in the industry, outperforming 68.75% of the companies in the same industry.
- In the last couple of years the Operating Margin of 56S1 has declined.
- 56S1 has a Gross Margin of 44.71%. This is in the better half of the industry: 56S1 outperforms 62.50% of its industry peers.
- In the last couple of years the Gross Margin of 56S1 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.88% | ||
| PM (TTM) | 8.99% | ||
| GM | 44.71% |
OM growth 3Y-16.3%
OM growth 5Y-7.16%
PM growth 3Y-29.07%
PM growth 5Y-12.64%
GM growth 3Y-4.79%
GM growth 5Y-2.9%
2. 56S1.DE Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), 56S1 is destroying value.
- Compared to 1 year ago, 56S1 has about the same amount of shares outstanding.
- The number of shares outstanding for 56S1 has been increased compared to 5 years ago.
- The debt/assets ratio for 56S1 has been reduced compared to a year ago.
2.2 Solvency
- 56S1 has an Altman-Z score of 3.45. This indicates that 56S1 is financially healthy and has little risk of bankruptcy at the moment.
- 56S1's Altman-Z score of 3.45 is amongst the best of the industry. 56S1 outperforms 87.50% of its industry peers.
- The Debt to FCF ratio of 56S1 is 7.10, which is on the high side as it means it would take 56S1, 7.10 years of fcf income to pay off all of its debts.
- With a Debt to FCF ratio value of 7.10, 56S1 perfoms like the industry average, outperforming 56.25% of the companies in the same industry.
- 56S1 has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
- With a decent Debt to Equity ratio value of 0.49, 56S1 is doing good in the industry, outperforming 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 7.1 | ||
| Altman-Z | 3.45 |
ROIC/WACC0.66
WACC9.33%
2.3 Liquidity
- 56S1 has a Current Ratio of 1.03. This is a normal value and indicates that 56S1 is financially healthy and should not expect problems in meeting its short term obligations.
- With a Current ratio value of 1.03, 56S1 is not doing good in the industry: 62.50% of the companies in the same industry are doing better.
- A Quick Ratio of 0.58 indicates that 56S1 may have some problems paying its short term obligations.
- The Quick ratio of 56S1 (0.58) is worse than 62.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.03 | ||
| Quick Ratio | 0.58 |
3. 56S1.DE Growth Analysis
3.1 Past
- 56S1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.71%, which is quite impressive.
- 56S1 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 1.13% yearly.
- The Revenue has been growing slightly by 4.43% in the past year.
- Measured over the past years, 56S1 shows a quite strong growth in Revenue. The Revenue has been growing by 9.21% on average per year.
EPS 1Y (TTM)25.71%
EPS 3Y-20.14%
EPS 5Y1.13%
EPS Q2Q%3.41%
Revenue 1Y (TTM)4.43%
Revenue growth 3Y-5.29%
Revenue growth 5Y9.21%
Sales Q2Q%2.27%
3.2 Future
- The Earnings Per Share is expected to grow by 18.07% on average over the next years. This is quite good.
- Based on estimates for the next years, 56S1 will show a quite strong growth in Revenue. The Revenue will grow by 10.28% on average per year.
EPS Next Y17.04%
EPS Next 2Y18.3%
EPS Next 3Y18.07%
EPS Next 5Y18.07%
Revenue Next Year7.37%
Revenue Next 2Y8.99%
Revenue Next 3Y9.53%
Revenue Next 5Y10.28%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. 56S1.DE Valuation Analysis
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 34.43 indicates a quite expensive valuation of 56S1.
- The rest of the industry has a similar Price/Earnings ratio as 56S1.
- When comparing the Price/Earnings ratio of 56S1 to the average of the S&P500 Index (26.54), we can say 56S1 is valued slightly more expensively.
- 56S1 is valuated rather expensively with a Price/Forward Earnings ratio of 24.60.
- 56S1's Price/Forward Earnings ratio is in line with the industry average.
- 56S1 is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 21.68, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.43 | ||
| Fwd PE | 24.6 |
4.2 Price Multiples
- 56S1's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 68.75% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of 56S1 is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 40.05 | ||
| EV/EBITDA | 19.62 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- The decent profitability rating of 56S1 may justify a higher PE ratio.
- A more expensive valuation may be justified as 56S1's earnings are expected to grow with 18.07% in the coming years.
PEG (NY)2.02
PEG (5Y)30.52
EPS Next 2Y18.3%
EPS Next 3Y18.07%
5. 56S1.DE Dividend Analysis
5.1 Amount
- With a yearly dividend of 0.44%, 56S1 is not a good candidate for dividend investing.
- The stock price of 56S1 dropped by -27.89% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
- Compared to an average industry Dividend Yield of 0.57, 56S1 has a dividend in line with its industry peers.
- Compared to an average S&P500 Dividend Yield of 1.82, 56S1's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.44% |
5.2 History
- On average, the dividend of 56S1 grows each year by 15.19%, which is quite nice.
Dividend Growth(5Y)15.19%
Div Incr Years0
Div Non Decr Years2
5.3 Sustainability
- 25.01% of the earnings are spent on dividend by 56S1. This is a low number and sustainable payout ratio.
- The dividend of 56S1 is growing around the same rate as the earnings are growing. If this keeps up the dividend growth is sustainable.
DP25.01%
EPS Next 2Y18.3%
EPS Next 3Y18.07%
56S1.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:56S1 (4/29/2026, 7:00:00 PM)
151.5
-8.2 (-5.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Industry Strength10.81
Industry Growth92
Earnings (Last)04-23 2026-04-23
Earnings (Next)07-23 2026-07-23
Inst Owners11.99%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap14.75B
Revenue(TTM)2.98B
Net Income(TTM)268.30M
Analysts84.21
Price Target227.25 (50%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.44% |
Yearly Dividend0.69
Dividend Growth(5Y)15.19%
DP25.01%
Div Incr Years0
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.45%
Min Revenue beat(2)-4.17%
Max Revenue beat(2)-0.72%
Revenue beat(4)1
Avg Revenue beat(4)-2.13%
Min Revenue beat(4)-4.17%
Max Revenue beat(4)0.3%
Revenue beat(8)4
Avg Revenue beat(8)-0.72%
Revenue beat(12)5
Avg Revenue beat(12)-1.61%
Revenue beat(16)5
Avg Revenue beat(16)-1.81%
PT rev (1m)-8.14%
PT rev (3m)-8.11%
EPS NQ rev (1m)-1.45%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-2.14%
EPS NY rev (3m)-3.5%
Revenue NQ rev (1m)0.77%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)-1.2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.43 | ||
| Fwd PE | 24.6 | ||
| P/S | 4.94 | ||
| P/FCF | 40.05 | ||
| P/OCF | 19.26 | ||
| P/B | 3.59 | ||
| P/tB | N/A | ||
| EV/EBITDA | 19.62 |
EPS(TTM)4.4
EY2.9%
EPS(NY)6.16
Fwd EY4.06%
FCF(TTM)3.78
FCFY2.5%
OCF(TTM)7.87
OCFY5.19%
SpS30.66
BVpS42.21
TBVpS-3.03
PEG (NY)2.02
PEG (5Y)30.52
Graham Number64.6436 (-57.33%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.28% | ||
| ROE | 6.53% | ||
| ROCE | 8.11% | ||
| ROIC | 6.19% | ||
| ROICexc | 6.75% | ||
| ROICexgc | 24.99% | ||
| OM | 17.88% | ||
| PM (TTM) | 8.99% | ||
| GM | 44.71% | ||
| FCFM | 12.34% |
ROA(3y)3.15%
ROA(5y)7.45%
ROE(3y)7.54%
ROE(5y)16.68%
ROIC(3y)5.23%
ROIC(5y)11.87%
ROICexc(3y)5.56%
ROICexc(5y)12.62%
ROICexgc(3y)18.67%
ROICexgc(5y)31.48%
ROCE(3y)6.85%
ROCE(5y)15.55%
ROICexgc growth 3Y-18%
ROICexgc growth 5Y-10.32%
ROICexc growth 3Y-31.81%
ROICexc growth 5Y-17.24%
OM growth 3Y-16.3%
OM growth 5Y-7.16%
PM growth 3Y-29.07%
PM growth 5Y-12.64%
GM growth 3Y-4.79%
GM growth 5Y-2.9%
F-Score8
Asset Turnover0.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 7.1 | ||
| Debt/EBITDA | 2.35 | ||
| Cap/Depr | 123.52% | ||
| Cap/Sales | 13.32% | ||
| Interest Coverage | 3.44 | ||
| Cash Conversion | 89.5% | ||
| Profit Quality | 137.23% | ||
| Current Ratio | 1.03 | ||
| Quick Ratio | 0.58 | ||
| Altman-Z | 3.45 |
F-Score8
WACC9.33%
ROIC/WACC0.66
Cap/Depr(3y)145.19%
Cap/Depr(5y)180.27%
Cap/Sales(3y)14.18%
Cap/Sales(5y)13.22%
Profit Quality(3y)157.37%
Profit Quality(5y)116.81%
High Growth Momentum
Growth
EPS 1Y (TTM)25.71%
EPS 3Y-20.14%
EPS 5Y1.13%
EPS Q2Q%3.41%
EPS Next Y17.04%
EPS Next 2Y18.3%
EPS Next 3Y18.07%
EPS Next 5Y18.07%
Revenue 1Y (TTM)4.43%
Revenue growth 3Y-5.29%
Revenue growth 5Y9.21%
Sales Q2Q%2.27%
Revenue Next Year7.37%
Revenue Next 2Y8.99%
Revenue Next 3Y9.53%
Revenue Next 5Y10.28%
EBIT growth 1Y32.86%
EBIT growth 3Y-20.72%
EBIT growth 5Y1.39%
EBIT Next Year53.61%
EBIT Next 3Y26%
EBIT Next 5Y21.51%
FCF growth 1Y117.61%
FCF growth 3Y18.06%
FCF growth 5Y3.02%
OCF growth 1Y20.36%
OCF growth 3Y4.17%
OCF growth 5Y10.67%
SARTORIUS STEDIM BIOTECH / 56S1.DE Fundamental Analysis FAQ
What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a fundamental rating of 4 / 10 to 56S1.DE.
Can you provide the valuation status for SARTORIUS STEDIM BIOTECH?
ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.
What is the profitability of 56S1 stock?
SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 5 / 10.
What are the PE and PB ratios of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
The Price/Earnings (PE) ratio for SARTORIUS STEDIM BIOTECH (56S1.DE) is 34.43 and the Price/Book (PB) ratio is 3.59.
Can you provide the dividend sustainability for 56S1 stock?
The dividend rating of SARTORIUS STEDIM BIOTECH (56S1.DE) is 4 / 10 and the dividend payout ratio is 25.01%.